Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older Study.

Background Older patients managed with intensive antidiabetic therapy are more likely to be harmed. Our study's primary endpoint was to analyze the safety and efficacy of linagliptin in combination with basal insulin versus basal-bolus insulin in patients with 75 years of age or older hospitalized in medicine and surgery departments in real-world clinical practice. Methods We retrospectively enrolled non-critically patients ≥75 years with type 2 diabetes admitted to medicine and non-cardiac surgery departments with admission glycated haemoglobin Results Post-matching, 198 patients were included in each group. There were no significant differences in mean daily blood glucose levels after admission (p=0.203); patients with mean blood glucose 100-140mg/dL (p=0.134), 140-180mg/dL (p=0.109), or >200mg/dL (p=0.299); and number and day of treatment failure (p=0.159 and p=0.175, respectively). The total insulin dose and the number of daily injections were significantly lower in the linagliptin-basal group (both, p Conclusions The linagliptin-basal insulin regimen was an effective alternative with fewer hypoglycemic events and daily insulin injections than intensive basal-bolus insulin in very old patients with type 2 diabetes with mild-to-moderate hyperglycemia treated at home without injectable therapies.